Sign In
Buy ABBV
$224.93
+7.86 (+3.62%)
At Close: Jun 04, 2026
Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock
10:01am, Tuesday, 03'rd Dec 2024
AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
3 High-Yield Dividend Growth Stocks to Buy in December and Hold for a Decade or Longer
04:24am, Tuesday, 03'rd Dec 2024
It's been a great couple of years for the stock market. From the end of 2022 through Nov. 29, the benchmark S&P 500 (^GSPC 0.24%) index rose a whopping 57.1% higher.
3 Fantastic Dividend Stocks to Buy Sooner Rather Than Later
05:52am, Sunday, 01'st Dec 2024
You don't have to be an income investor to like dividends. Many billionaires who definitely don't need income still have dividend stocks in their portfolios.
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever
05:41am, Saturday, 30'th Nov 2024
What's better than receiving passive income? Enjoying it for decades.
Why Is AbbVie (ABBV) Down 10.2% Since Last Earnings Report?
12:38pm, Friday, 29'th Nov 2024
AbbVie (ABBV) reported earnings 30 days ago. What's next for the stock?
Forget Big Tech - I'll Take Dividend Stalwarts Any Day
07:30am, Friday, 29'th Nov 2024
Big Tech dominates markets but faces risks like slowing growth, AI dependency, and inflated valuations. Dividend stalwarts offer a safer, smarter alternative. Dividend stocks, like those in VYM and SC
My Best Dividend Aristocrats For December 2024
07:07am, Tuesday, 26'th Nov 2024
The ProShares S&P 500 Dividend Aristocrat ETF is up 10.26% year-to-date through October. I present 3 strategies that can theoretically beat the dividend aristocrat index in the long term. After 40 mon
2 High-Yield Dividend Stocks to Buy Now for a Lifetime of Passive Income
05:03am, Tuesday, 26'th Nov 2024
Investors looking for a way to pump up their passive income streams want to turn their attention toward the pharmaceutical industry. From the end of 2022 through Nov. 22, the benchmark S&P 500 index r
Despite Neuroscience Setback, AbbVie Has Strong Recovery Ahead
06:27pm, Monday, 25'th Nov 2024
AbbVie's stock dropped 17.3% due to Emraclidine's phase 2 trial failure, but management is expected to replace Humira revenues and grow the top line. Skyrizi and Rinvoq are projected to surpass Humira
AbbVie Stock Rises After Leerink Partners Upgrades Its Rating
04:00pm, Monday, 25'th Nov 2024
Leerink Partners upgrades its rating on ABBV stock from Market Perform to Outperform.
One Sector Has Underperformed Massively: These 4 Blue-Chip Dividend Giants Are Huge 2025 Plays
11:46am, Monday, 25'th Nov 2024
Key Points Donald Trump's victory is positive for the stock market.
AbbVie Digital Transformation Strategy Report 2024 - Technology Focus, Technology Initiatives, ICT Budget and Contracts
11:02am, Monday, 25'th Nov 2024
Dublin, Nov. 25, 2024 (GLOBE NEWSWIRE) -- The "Enterprise Tech Ecosystem Series: AbbVie Inc. - 2024" company profile has been added to ResearchAndMarkets.com's offering.
AbbVie to Present at Citi's 2024 Global Healthcare Conference
08:00am, Monday, 25'th Nov 2024
NORTH CHICAGO, Ill. , Nov. 25, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in Citi's 2024 Global Healthcare Conference on Tuesday, December 3, 2024.
Dividend Aristocrats Yielding Over 4% to Buy in November
12:39pm, Saturday, 23'rd Nov 2024
Companies with high dividend yields are relatively uncommon in this market.
The Stock Market Is Soaring but These 2 Stocks Are Still Dirt Cheap Buys
09:17am, Saturday, 23'rd Nov 2024
Earlier this month, the S&P 500 hit a record high of more than 6,000 for the first time ever. Based on that, you might assume that stocks may be too expensive to buy right now as the average stock in
